Trinity College Dublin, St. James's Hospital, James's Street, Dublin 2, Ireland.
Ir J Med Sci. 2012 Jun;181(2):211-4. doi: 10.1007/s11845-011-0780-7. Epub 2011 Nov 3.
The combination chemotherapy regimen of streptozocin and 5-fluorouracil (FU/STZ) has been used for the treatment of metastatic neuroendocrine tumours.
The aim of this study was to analyse the use of this regimen in a tertiary oncology referral centre over a 10-year period.
We retrospectively analysed nine cases from February 2000 to May 2010. Patient demographics, chemotherapy schedule, toxicities, progression-free and overall survival were tabulated for each patient.
The median progression-free survival was 17 months (range 3-48+ months), and overall survival 31 months (range 12-53+ months) with no toxicity related deaths.
FU/STZ was a well-tolerated regimen that produced significant benefit in the setting of metastatic and progressive disease. Our case series demonstrated comparable progression-free survival and overall survival in relation to randomized controlled studies and previous case series.
链脲佐菌素和 5-氟尿嘧啶（FU/STZ）联合化疗方案已被用于治疗转移性神经内分泌肿瘤。
本研究旨在分析在一个三级肿瘤转诊中心使用该方案的 10 年期间的情况。
我们回顾性分析了 2000 年 2 月至 2010 年 5 月的 9 例患者。对每位患者的患者人口统计学、化疗方案、毒性、无进展生存期和总生存期进行了制表。
中位无进展生存期为 17 个月（范围 3-48+个月），总生存期为 31 个月（范围 12-53+个月），无毒性相关死亡。
FU/STZ 是一种耐受性良好的方案，在转移性和进展性疾病的治疗中产生了显著的获益。我们的病例系列显示，与随机对照研究和以前的病例系列相比，无进展生存期和总生存期相当。
